Urokinase is a basic biologic product that can be used in a wide range of
pathologic processes. For everyone to explain the introduction of urokinase
basic pharmacological action what, the following specific understanding.
Urokinase itself does not bind to fibrin, but directly acts on the
plasminogen on the surface of blood clots to break the arginine-valine bond in
the plasminogen molecule, resulting in the thrombolytic effect of plasminogen.
The presence of urokinase receptors on endothelial and monocyte surfaces
increases the catalytic activity of UK. Urokinase is an endogenous plasminogen
activator contained in human plasma and urine.
Precautions before application, thrombolytic adverse indications, impact
administration and treatment of thrombolytic complications are the same as SK,
as detailed in the previous section of this chapter. The importance of positive
diagnosis must be emphasized before thrombolytic therapy. Powder for urokinase
injection was dissolved with 5ml water for injection and diluted with 0.9%
normal saline or 5% glucose. This product can not be diluted with acidic liquid,
lest its efficacy decrease. It is recommended to filter UK through a 0.45μm
aperture filter membrane before infusion.
The basic pharmacological action of urokinase is sorted out and shared
above, hoping to help you understand the product. We will continue to share with
you in the future. Welcome to continue to follow us.